General Information of Drug (ID: DMD2P1X)

Drug Name
QPX7831
Indication
Disease Entry ICD 11 Status REF
Gram-negative bacterial infection 1B74-1G40 Phase 1 [1]
Cross-matching ID
TTD ID
D2UE8B

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Staphylococcus Beta-lactamase (Stap-coc blaZ) TTHI19T BLAC_STAAU Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04578873) A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Single- and Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of Oral QPX7831 in Healthy Adult Subjects. U.S.National Institutes of Health.
2 Selection of QPX7831, an Orally Bioavailable Prodrug of Boronic Acid beta-Lactamase Inhibitor QPX7728. J Med Chem. 2021 Dec 9;64(23):17523-17529.